Medical Equipment and Supplies Manufacturing (U.S.) — Industry-Group Rollup Primer

NAICS 2022 code 3391. A Histometrics rollup primer for public-market and private investors. This is a four-digit industry group that contains exactly one five-digit industry, 33911, so this level and its one child are effectively the same thing — read this page for the ground-truth numbers at this level, then go to the 33911 primer for the full detail.

1. Overview

NAICS (the North American Industry Classification System, the U.S. government's standard code for industries) is a nested hierarchy: a four-digit industry group normally bundles several five-digit industries beneath it. Code 3391 is the unusual case where the bundle has only one item. The industry group "Medical Equipment and Supplies Manufacturing" and the industry beneath it, 33911 (same name), cover the identical set of factories: the makers of the physical, non-electronic goods clinicians use on and inside patients — surgical instruments, catheters and syringes; orthopedic and spinal implants, wound care and prosthetics; dental chairs, implants and clear aligners; eyeglass and contact lenses; and custom crowns and dentures.[1][2]

What sits outside this level matters as much as what sits inside, because it is where the largest "medtech" dollars are: the electronic and imaging machines — pacemakers, defibrillators, patient monitors, MRI, CT and ultrasound — are classified in 334510 Electromedical Apparatus and 334517 Irradiation Apparatus, separate codes entirely. So 3391 is the mechanical, material and single-use half of the device economy, not the electronics half.[2]

Because the two levels are numerically identical, this page is deliberately short. It states 3391's own federal ground-truth figures and explains the pass-through; all of the analysis — what the sub-industries make, where value concentrates, how the money works, and how to invest — lives in the 33911 primer.[2]

2. What's inside — and why this level equals its one child

A four-digit industry group can hold up to nine five-digit industries. NAICS 3391 holds just one:

With a single child, the parent inherits every number and every characteristic of the child with nothing added or removed — 3391's shipments, firms, employment and concentration are 33911's. The economically meaningful split happens one level further down, inside 33911, which itself divides into five national industries: surgical instruments (339112), surgical appliances and implants (339113), dental equipment (339114), ophthalmic goods (339115) and dental laboratories (339116).[2]

That five-way split is where all the contrast sits, and the revised child sharpens it into four facts an investor should carry into the detail page. Receipts are lopsided: instruments (~42%, ~$40.3B) and appliances/implants (~39%, ~$37.9B) are ~81% of the level, leaving roughly 6–7% each for dental equipment (~$5.8B), ophthalmic goods (~$6.5B) and dental labs (~$6.3B).[2] Labor intensity splits the level in two: revenue per worker runs roughly $280K–$400K in the four manufacturing children but only ~$150K in dental laboratories, a made-to-order craft trade — which is why dental labs are ~6.5% of receipts yet ~14% of the jobs and 58% of all firms in the level (4,669 of ~7,900, averaging about $1.4M of revenue apiece), while the average surgical-instrument establishment employs about 101 people.[2] Pay splits the same way: surgical instruments pays about $93,000 per employee against a level average near $83,500, while the mean U.S. dental-laboratory technician earned about $52,400 in May 2024 — one NAICS code containing both a validated-cleanroom workforce and a low-wage craft trade.[1][2] And direction of travel is not uniform: four children face a rising long-run demand curve; dental laboratories are structurally threatened from two sides at once as dentists mill and print crowns chairside and offshore labs undercut domestic pricing, with BLS projecting lab-technician employment down 4.7%, from 35,200 in 2024 to 33,600 in 2034.[2] There is nothing at the 3391 level that is not already 33911.

One boundary quirk is worth knowing before reading the child, because it moves real money between sub-industries: intraocular lenses — the implants placed in the eye during cataract surgery — are classified in 339113 rather than ophthalmic goods, and ophthalmic surgical instruments and lasers in 339112. The level therefore captures far more of the eye-care manufacturing chain than the ophthalmic child alone suggests. The same logic runs the other way in dentistry: making a zirconia blank is 339114, but milling a specific patient's crown from it is 339116.[2]

3. How big it is (this level's rollup figures)

Federal ground-truth for the whole of NAICS 3391 (identical to 33911, since they are the same set of establishments):

At ~$97 billion in domestic factory shipments, this is a large manufacturing group, and its ~$83,500 average pay sits well above the U.S. manufacturing average — skilled, cleanroom, quality-controlled work.[1] The five national industries beneath reconcile to these figures on establishments and payroll essentially to the rounding; their firm counts sum a little higher than 7,941, which is what you expect when a company operating plants in two of them is counted once in each.[2]

Concentration looks deceptively low, and the revised child now shows exactly why. "CR4/CR8/CR20/CR50" are concentration ratios (the combined revenue share of the largest 4, 8, 20 and 50 firms); the HHI is the Herfindahl-Hirschman Index, a standard 0–10,000 concentration score. At CR4 19.3% and HHI 164, 3391 reads as almost perfectly competitive — but that is an artifact of bundling five unrelated sub-industries: no company competes across all of them, so no firm's share piles up at this level. Every one of the five children is more concentrated than 3391 itself, from an HHI of 173.1 in dental laboratories and 271 in surgical instruments up to 417.7 in surgical appliances and roughly 665 in dental equipment; ophthalmic goods is the most concentrated of all on a CR4 of 59.3% (top eight, 73.3%), though its HHI is suppressed in federal data.[2] Note that concentration runs roughly inversely to size here — the two children carrying ~81% of receipts are among the least concentrated, while one of the smallest is by far the most. All of these readings still sit below the 1,500 line antitrust agencies treat as "moderately concentrated," yet inside any single niche the reality is an oligopoly (Section 8). Read the low HHI as "five separate contests," not "easy entry."[1][2]

Undercount caveat — read before comparing to company revenues. The $96.83B is domestic factory shipments by establishments primarily in this code [1]. It is not U.S. spending on this equipment, for three reasons: (1) a large share of devices, frames, components and dental restorations sold in the U.S. is imported and never appears in domestic shipments — one estimate puts roughly 14% of U.S.-marketed medical devices as made in China, about three-quarters of personal protective equipment as imported, and China as the single largest source of eyewear; (2) the diversified medtech giants straddle this code, the excluded electromedical codes and overseas markets, so you cannot add up the companies in Section 4 to reach $97B — Align, Dentsply Sirona and Envista alone report worldwide revenue larger than the entire $5.8B domestic dental-equipment child; and (3) small/individual ownership is under-captured, sharpest in dental labs, where thousands of tiny private shops sit alongside work that is offshored or performed in-house by dentists and optical retailers and lands in other codes entirely (a crown milled inside a dentist's office is counted under offices of dentists). Private "market size" estimates for the dental-lab trade alone range from about $2.4B to nearly $8B depending on what they bundle in.[2]

For scale, the broader U.S. medical-device market is estimated near $191 billion (2025), with the United States accounting for roughly 46% of global device sales in 2024; The Vision Council valued the 2025 U.S. optical ecosystem — exams, retail, contacts, lenses, frames, readers and sunglasses — at $69.5 billion; and U.S. dental services spending was $189.2 billion in 2024.[2] All are far larger than this level's $97B of domestic manufacturing, which cleanly measures making the goods, not consuming them.

4. The investable universe — where value concentrates

Because 3391 equals 33911, the investable map is 33911's. In brief: public-market access is extremely uneven across the five sub-industries. Listed opportunity clusters in the two big children — surgical instruments and implants (~81% of the level) — home to the large-cap medtech names; the three small children are dominated by foreign or diversified companies or barely listed at all. Dental equipment offers just three near-pure-play mid-caps; ophthalmic goods has no U.S. pure play and no dedicated eyewear ETF; dental laboratories have essentially no listed play at all, leaving only indirect exposure through the equipment makers or one Hong Kong-listed operator.[2] The one genuinely new access point since the last pass is Medline (MDLN), which completed its IPO in December 2025 and gives public investors direct exposure to the largest U.S. medical-surgical consumables platform — $28.4B of 2025 net sales — though roughly half of that is distribution rather than own-brand manufacturing, at a 26.4% consolidated gross margin.[2]

Private capital is the mirror image, concentrating exactly where public access is thinnest — contract manufacturers and CDMOs feeding the two surgical children (a global segment estimated near $89 billion in 2025, still fragmented among several hundred companies and an active roll-up target), orthopedic, prosthetics and dental-lab roll-ups, and DSO (Dental Service Organization) and optical-lab platforms.[2] The specific tickers, private-equity platforms and ETFs are laid out in Section 4 of the 33911 primer.[2]

5. How the money works

One dominant profit engine and one dominant constraint run across the level. The engine is razor-and-blades economics — pairing a durable good (a surgical robot, a dental scanner, a lens fitting) with a recurring stream of single-use consumables and per-case fees sold again and again against a growing installed base. The revised child quantifies it: instruments, accessories, service and leases were $8.5B of Intuitive Surgical's $10.1B 2025 revenue (84% recurring); more than two-thirds of Stryker's U.S. knee procedures ran on its MAKO robots by end-2025; and consumables, service and spare parts are about 70% of Envista's Equipment & Consumables segment.[2]

The margin spread across the level is wider than "branded medtech" implies — a correction worth carrying. Branded device makers cluster at 50–67% gross margin (Align 67%, Stryker 64%, Envista 55%, Dentsply Sirona 50%), protected by patents, FDA clearance and clinician switching costs; the consumable, contract and distribution tiers are a different business, at 26–38% (ICU Medical 38% in Q4 2025, Medline 26.4% consolidated in 2025).[2] Mixing the tiers into one "medtech margin" is the fastest way to misprice the level.

Price is capped by concentrated buyers — hospital Group Purchasing Organizations (typically extracting 10–18% off list), the Centers for Medicare & Medicaid Services (CMS) reimbursement schedules, dental DSOs and distributors, and vision-insurance plans plus vertically integrated retail chains. Volume, not price, is what moves the top line even for strong suppliers: Stryker's 2025 constant-currency organic growth was 9.9% volume and only 0.4% price.[2] Two exceptions matter: dental and premium optical work is largely cash-pay and therefore cyclical, and dental laboratories run a per-unit labor job shop, not a razor-and-blades model, where payroll runs on the order of a third of receipts. A third exposure runs beneath the brands — real single-customer concentration in the supplier and channel tiers (contract manufacturer Integer disclosed three customers at 49% of 2025 sales; Henry Schein alone was 13% of Dentsply Sirona's). Full detail is in Section 5 of the 33911 primer.[2]

6. Demand drivers

The master driver is aging and chronic disease — the U.S. population aged 65 and older rose 9.4% between 2020 and 2023 to roughly 59.2 million, and the Census Bureau projects that adults 65+ will outnumber children under 18 beginning in 2029 — which lifts surgical volume, joint and spine replacement, wound care, dental restoration and stronger eyeglass prescriptions across every sub-industry.[2] Layered on top: technology adoption within each child (minimally invasive and robotic surgery, which consumes more single-use instruments per case; digital dentistry; premium and myopia-control lenses), site-of-care shifts toward lower-cost ambulatory surgery centers, and buyer-structure shifts as DSOs went from about 100 in 2010 to over 2,000, now covering 30%+ of U.S. dentists.[2]

Two gates on that demand deserve more weight than the previous version of this page gave them. Reimbursement and affordability decide which volume is profitable — traditional Medicare covers only one pair of eyeglasses or contacts after cataract surgery, and only 45% of the U.S. population saw a dentist in 2022. And access and staffing are a genuinely level-wide brake, not a dental curiosity: HRSA counted 70.6 million people in designated dental shortage areas as of March 2026, and ADA reported in April 2026 that 91% of dentists recruiting hygienists found it extremely challenging. Fewer staffed chairs — or fewer cleanroom and lab technicians — cap procedure and consumable volumes regardless of underlying need.[2] A few isolated drivers round it out: the childhood myopia epidemic (ophthalmic, now with FDA-authorized products behind it), adult aesthetics driving clear aligners, single-use-device reprocessing as a substitute that can reduce new-unit demand, and GLP-1 weight-loss drugs as a two-way wildcard for orthopedics.[2] See Section 6 of 33911.

7. Regulation

One regulator ties the level together: nearly everything here is an FDA-regulated medical device (the U.S. Food and Drug Administration), risk-classified I, II or III, which sets the market-entry pathway — most products clear via a 510(k) premarket notification (showing "substantial equivalence" to an existing device, with a De Novo route for novel low-to-moderate-risk products), while the highest-risk implants need full Premarket Approval (PMA). Note the terminology trap: "FDA cleared" (510(k)) is not "FDA approved" (PMA).[2] The reach is broader than it looks — even ordinary spectacles and sunglasses are devices, and the child's revised research finds that dental laboratories are not comfortably exempt either: FDA's custom-device exemption is limited to no more than five units per year of a device type, and a June 2025 warning letter rejected the argument that patient-specific partial dentures made from cleared materials were exempt lab service.[2]

Level-wide currents to watch:

• Quality-system overhaul, now in force. The FDA's Quality Management System Regulation (QMSR) took effect February 2, 2026, folding in the international ISO 13485:2016 standard — harmonizing U.S. rules globally but expanding what inspectors may review and raising compliance cost for every covered manufacturer.[2]
• Sterilization is the level's newest live constraint, and it was absent from the previous version of this page. FDA estimates roughly 50% of sterile U.S. medical devices are sterilized with ethylene oxide (EtO), often the only practical method for polymers and complex devices such as catheters. EPA's 2024 emissions rule targeted reductions above 90% at nearly 90 commercial sterilization facilities, but EPA proposed repealing it in March 2026 — leaving both the rule and sterilizer capacity planning uncertain for the two heavyweight children.[2]
• Tariffs, now quantified rather than asserted. 2025-era tariffs on imported devices, components, frames and dental goods remain a live cost pressure given the level's high import dependence; one large maker guided to roughly $400M of 2025 tariff expense, and Medline attributed a 115-basis-point cut to its 2025 gross margin and a $290 million adverse pretax effect to tariffs and related developments.[2]
• FDA capacity. Early-2025 federal workforce reductions cut roughly 180 CDRH staff, raising industry concern about review timelines — a risk to watch rather than a settled fact.[2]

Child-specific regimes (CMS payment rules including the mandatory Transforming Episode Accountability Model from January 1, 2026, the FTC Contact Lens Rule, the dental-amalgam phase-down, state dental-lab registration) are detailed in Section 7 of the 33911 primer.[2]

8. Consolidation

Consolidation is the level's default motion in two forms. In the two heavyweights (instruments, implants), incumbents pursue acquire-approved-product-line M&A — buying cleared, revenue-generating portfolios because FDA clearance, surgeon training and hospital relationships are the scarce assets (Globus Medical–NuVasive ~$3.1B in 2023, Zimmer Biomet–Paragon 28 ~$1.2B in 2025). In the three small children, consolidation runs through financial-buyer roll-ups and take-privates — DSO networks, distributor buyouts (Patterson to Patient Square, ~$4.1B, closed April 2025), manufacturer buyouts (ZimVie to ArchiMed, ~$730M) and dental-lab roll-ups such as Cerberus-backed National Dentex, now 55+ laboratories.[2]

The revised child adds a direction the previous version of this page missed: the flow runs both ways. Johnson & Johnson has said it will spin off its DePuy Synthes orthopaedics business (roughly $9.2B), Solventum exists only because 3M spun it out, and Medline's December 2025 IPO added a major listed platform — the giants break themselves apart as readily as they bolt things on, and not every deal lands (Alcon's agreed takeover of STAAR Surgical was rejected by shareholders and terminated in January 2026).[2] The level's low HHI understates all of this, because within any single niche the reality is an oligopoly: the top four hold roughly 80%+ of U.S. knee and hip implants and close to 80% of spine, the top five in advanced wound care hold ~45–50%, and contact lenses are a global "Big Four."[2] Section 8 of 33911 has the deal specifics.

9. Risks

The shared risk stack: pricing power sits with the buyer (hospitals and GPOs, CMS, DSOs, vision plans); tariffs and import dependence, now sized at per-device impacts of $2,000–$8,000 on complex devices, ~150%+ combined rates on some Chinese optical goods, and Medline's $290M pretax hit; a sterilization bottleneck new to this page, where roughly half of sterile devices depend on ethylene oxide and any capacity loss or hurried transfer can interrupt supply outright; regulatory, recall and product-liability exposure, heaviest in implanted and invasive products, with the QMSR transition raising compliance cost; concentration risk in the supplier and channel tiers (contract manufacturers, distributors, DSO contracts that can be insourced, sole-source inputs); technology disruption, sharpest as chairside milling and offshoring disintermediate dental labs — the one sub-industry whose domestic pie is flat-to-shrinking; and skilled-labor scarcity in cleanroom and dental-lab technicians.[2]

One correction the revised child forces on any rollup at this level: demand is not a smooth line, even where it trends up. Surgical appliances' real sectoral output fell about 8.2% from 2022 to 2023 as pandemic PPE demand normalized, and U.S. optical product volumes and eye exams declined in 2025 even as higher prices lifted market value.[2] "Healthcare demand always rises" is an inadequate forecasting rule here. Detailed in Section 9 of the 33911 primer.

10. How to invest & outlook

Match the route to the sub-industry. Public-market investors get the cleanest access to the two big children through diversified medtech names and the medical-device ETFs — IHI (0.38% expense ratio) and XHE (0.35%) — which also hold the excluded electromedical names, making them a broad "medtech" bet rather than a pure 3391 bet.[2] Underwrite the relevant product franchise rather than consolidated revenue: the giants book sales across both big children, the excluded codes and overseas, and roughly half of Medline's revenue is distribution.[2] Private-market investors get disproportionate access to the three small children and the supplier tiers — contract manufacturers and CDMOs, orthopedic, prosthetics and dental-lab roll-ups, DSO and optical-lab platforms — the same demographic tailwinds without the branded-incumbent premium, at the cost of liquidity and single-asset regulatory risk. The diligence questions converge across all five: recurring/consumable mix and installed-base pull-through, FDA pathway and inspection history, recall exposure, customer concentration, sole-source inputs and sterilization dependence, validated capacity, and — in the craft trades — technician retention, remake rates and domestic/offshore mix. Reserve valuation, yield and multiple judgments for a security-specific screen, noting that income is thin in the dental names.[2]

Outlook. The structural case is durable and demographically anchored — aging, chronic disease, the shift to minimally invasive and robotic surgery, digital dentistry and the myopia epidemic should keep unit volumes and recurring revenue growing at a mid-single-digit pace, with faster niches (clear aligners ~15%/yr, dental implants ~8.5%/yr, advanced wound care mid-to-high single digits) running higher. The honest exception is dental labs.[2] Two caveats belong alongside it. First, the long-run demand curve and the year-to-year output series are not the same thing — a real output decline in surgical appliances and falling optical volumes sit inside an otherwise rising trend. Second, the near-term swing factors are policy and cost, not demand: how far tariffs compress margins, whether FDA review capacity and the now-in-force QMSR hold up, whether ethylene-oxide sterilization capacity stays available while EPA reconsiders its 2024 rule, and how hard consolidated buyers squeeze price.[2] This is a policy- and trade-exposed manufacturing level, not a purely defensive one. For the whole story, read the 33911 primer.

---

Sources

1. U.S. Census Bureau. 2022 Economic Census (receipts, firms, CR4/CR8/CR20/CR50, HHI) and County Business Patterns 2023 (establishments, employment, annual and Q1 payroll) — NAICS 3391 / 33911. Our ingested federal ground-truth statistics for this level; at 3391 they are identical to 33911 because the group has one child. 2022–2023. https://www.census.gov/programs-surveys/economic-census.html
2. Histometrics leaf primer — Medical Equipment and Supplies Manufacturing (NAICS 33911), the single child of 3391, which in turn synthesizes its own five national-industry primers (339112 surgical instruments, CR4 ~26% / HHI 271; 339113 surgical appliances, CR4 35.1% / HHI 417.7 and real output −8.2% 2022→2023; 339114 dental equipment, CR4 ~45% / HHI ~665; 339115 ophthalmic goods, CR4 59.3% / CR8 73.3%; 339116 dental laboratories, CR4 24.1% / HHI 173.1) together with U.S. Census (2022 EC / 2023 CBP), BLS output, wage and employment projections (dental-lab technicians $52,400 mean May 2024; 35,200 in 2024 → 33,600 in 2034), FDA device-classification and 510(k)/De Novo/PMA guidance, the QMSR effective February 2, 2026, FDA and EPA ethylene-oxide materials (2024 rule and 2026 proposed repeal), the June 2025 Reset Technology warning letter, CMS reimbursement and National Health Expenditures (U.S. dental services $189.2B in 2024), HRSA and ADA access and staffing data, The Vision Council's 2025 U.S. optical estimate ($69.5B), the U.S. medical-device market (~$191B, U.S. ~46% of global sales), company filings (including Medline's 2025 Form 10-K, $28.4B sales, 26.4% gross margin, $290M tariff impact), tariff analyses, ETF fund documents, and 2023–2026 M&A, IPO and spin-off activity. This is the full-detail primer that 3391 passes through to.